← All Capricor Therapeutics, INC filings

Capricor Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
CAPR
Capricor Therapeutics, INC
10-K: Capricor Therapeutics: Deramiocel BLA Resubmission & HOPE-3 Data
Capricor Therapeutics' Deramiocel for Duchenne muscular dystrophy receives a new FDA PDUFA target action date of August 22, 2026, following positive Phase 3 HOPE-3 trial results and a resubmission addressing a prior Complete Response Letter.
NASDAQ
CAPR
Capricor Therapeutics, INC
10-K: Capricor Therapeutics Submits 10-K Filing, Highlights BLA Acceptance and Priority Review for DMD Treatment
Capricor Therapeutics' 10-K filing details the company's progress, including FDA acceptance of its BLA for deramiocel in DMD cardiomyopathy and priority review status.
NASDAQ
CAPR
Capricor Therapeutics, INC
10-K: Capricor Therapeutics Outlines Share Structure and Regulatory Framework in 10-K Filing
Capricor Therapeutics' 10-K filing details its capital structure, stock information, and regulatory landscape, emphasizing its focus on cell and exosome-based therapies.